PDF
ePub
Citation
Print
Abstract
Purpose
Cyclooxygenase (COX) is an enzyme that catalyzes the conversion of arachidonic acid to prostaglandins. The inducible form, COX-2, is induced by such proinflammatory and mitogenic stimuli as cytokines and growth factors, and it's expressed in inflamed tissues as well as neoplastic tissues. In addition, COX-2 inhibitors have been tried as chemopreventive agents in tumors. In order to elucidate the mechanisms of COX-2 inhibitors in human breast cancer, the effects of celecoxib, a well-known selective COX-2 inhibitor, on cell death in human breast MDA-MB-468 cancer cells were investigated.
Methods
Cell viability assay, PI staining, DNA fragmentation assay and western blot analysis were performed after treatment with celecoxib.
Results
Cell survival, as measured by MTT assay, was decreased by the treatment with celecoxib in a dose-dependent manner (IC50=50 µM). The sub-G1 fractions, analyzed by flow cytometry, and the DNA fragmentations were increased in a dose-dependent manner, suggesting that celecoxib induces apoptotic cell death in MDA-MB-468 cells. Celecoxib resulted in a decrease in the levels of COX-2 protein in a time-depended and dose-dependent manner. To investigate the mechanisms of celecoxib-induced apotosis, the activation of MAPK, NF-kB and Akt was analyzed by Western blotting. The treatment with celecoxib induces an increase in JNK phosphorylation and IkB degradation and a decrease in Akt phosphorylation.
References
1. Surh YJ. Bioactivation of benzylic and allylic alcohols via sulfo-conjugation. Chem Biol Interact. 1998. 109:221–235.
2. Spinella MJ, Kerley JS, White KA, Curtin JC. Retinoid target gene activation during induced tumor cell differentiation: human embryonal carcinoma as a model. J Nutr. 2003. 133:273S–276S.
3. Katiyar SK. Silymarin and skin cancer prevention: Anti-inflammatory, antioxidant and immunomodulatory effects. Int J Oncol. 2005. 26:169–176.
4. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, et al. Cyclo-oxygenase 2: a parmacological target for the prevention of cancer. Lancet Oncol. 2001. 2:544–551.
5. Song H, Koo TY, Park JH, Song KH, Kim ST. Inhibition of cyclooxygenase-2 (COX-2) expression by genistein in breast. J Korean Breast Cancer Soc. 2003. 6:277–282.
6. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J. 1998. 12:1063–1073.
7. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002. 190:279–286.
8. Eschwege P, de Ledinghen V, Camilli T, Kulkarni S, Dalbagni G, Droupy S, et al. Arachidonic acid and prostaglandins, inflammation and oncology. Presse Med. 2001. 30:508–510.
9. Surh YJ. Cyclooxygenase-2 as a molecular target for cancer chemopreventive agents. J Toxicol Public Hlth. 2001. 17:89–96.
10. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticanceagents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002. 94:252–266.
11. Smith WL, Meade EA, DeWitt DL. Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994. 744:50–57.
12. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res. 1997. 3:1679–1683.
13. Pelzmann M, Thurnher D, Gedlicka C, Martinek H, Knerer B. Nimesulide and indomethacin induce apoptosis in head and neck cancer cells. J Oral Pathol Med. 2004. 33:607–613.
14. MacGregor DJ, Kim YS, Sleisenger MH, Johnson LK. Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse. Int J Oncol. 2000. 17:173–179.
15. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostatic cancer cells. J Natl Cancer Inst. 2002. 94:585–591.
16. Hsu AL, Ching TT, Wang DS, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000. 275:11397–11403.
17. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther. 2004. 3:1421–1426.
18. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res. 2004. 2:632–642.
19. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997. 94:3336–3340.
20. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, et al. A selective cyclooxygenase 2 inhibitor surpresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology. 1997. 113:1883–1891.
21. Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995. 83:493–501.
22. Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, et al. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett. 1999. 460:145–148.
23. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996. 87:803–809.
24. Bitomsky N, Bohm M, Klempnauer KH. Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene. 2004. 23:7484–7493.
25. Kanda H, Miura M. Regulatory roles of JNK in programmed cell death. J Biochem (Tokyo). 2004. 136:1–6.
XML Download